Enhanced Treatment of Cholestatic Diseases with Elafibranor

The present inventive concept discloses direct improvements and enhancements to the original patent, focusing on optimizing elafibranor-based treatment regimens for cholestatic diseases, specifically Primary Biliary Cholangitis (PBC) and Primary Sclerosing Cholangitis (PSC).

The original patent disclosed methods of treatment of cholestatic diseases using elafibranor. However, it had limitations in terms of personalized treatment, dosing optimization, and risk reduction of adverse effects. The present inventive concept addresses these limitations by introducing novel components and approaches to enhance the efficacy and safety of elafibranor-based treatments.

The new inventive concept comprises a system for treating cholestatic diseases, which includes a monitoring module to track patient response to treatment and an adjustment module to adapt treatment regimens based on said response. Additionally, the concept involves a method for optimizing elafibranor dosing in patients with PBC by determining bile acid precursor C4 levels and adjusting the dosage accordingly. Furthermore, a composition for treating cholestatic diseases is disclosed, comprising elafibranor and a bile acid sequestrant, which enhances the efficacy of elafibranor. A system for personalized treatment of PBC is also introduced, utilizing a database of patient profiles and a treatment algorithm to recommend elafibranor dosing regimens. Finally, a method for reducing the risk of adverse effects associated with elafibranor treatment in patients with PBC is disclosed, involving monitoring liver enzyme levels and adjusting the dosage based on said levels.

The new inventive concept introduces novel components and approaches that are not obvious from the original patent, including the use of a monitoring module, adjustment module, bile acid precursor C4 levels, bile acid sequestrant, patient profile database, and treatment algorithm. These components and approaches provide a non-obvious solution to the limitations of the original patent, enhancing the efficacy and safety of elafibranor-based treatments.

Alternative embodiments of the inventive concept could include the use of different monitoring modules, such as wearable devices or mobile applications, to track patient response to treatment. Additionally, various adjustment modules could be used, such as machine learning algorithms or artificial intelligence systems, to adapt treatment regimens. Furthermore, different bile acid sequestrants could be used in the composition, and various treatment algorithms could be employed in the system for personalized treatment of PBC.

The enhanced treatment of cholestatic diseases with elafibranor has significant commercial potential in the pharmaceutical industry, particularly in the areas of personalized medicine and treatment optimization. The target market includes patients with PBC and PSC, as well as healthcare providers and pharmaceutical companies seeking to improve treatment outcomes and reduce healthcare costs.